Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30thBusiness Wire • 11/23/21
Cortexyme's Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer's Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021Business Wire • 11/11/21
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11thBusiness Wire • 11/04/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cortexyme, Inc. - CRTXPRNewsWire • 11/04/21
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease ProgressionBusiness Wire • 10/26/21
SA Interview: Investing In The Pharmaceutical Industry With Small Pharma AnalystSeeking Alpha • 10/16/21
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease at CTAD 2021Business Wire • 09/27/21
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588Business Wire • 09/08/21
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13thBusiness Wire • 09/07/21
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer's Disease at Annual Biomarkers for Alzheimer's Disease SummitBusiness Wire • 08/25/21
Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst CaseBenzinga • 08/16/21